<h4>Introduction</h4>The advent of prostate-specific membrane antigen - positron emission tomography (PSMA-PET) imaging influences prostate cancer (PCa) salvage radiotherapy (SRT) decision-making, especially in biochemical recurrence (BCR) with low PSA. This evidence concerns the gene FOLH1 and posterior cortical atrophy.